A new study from the University of Basel indicates that fampridine, a drug currently prescribed to improve walking ability in multiple sclerosis (MS) patients, may also benefit individuals experiencing reduced working memory associated with mental health conditions such as schizophrenia and depression. The findings were published in the journal Molecular Psychiatry.
Working memory is crucial for everyday tasks, such as remembering a code long enough to enter it or engaging in a conversation. Impairments in working memory can significantly affect individuals, leading to difficulties in maintaining focus during discussions and organizing thoughts. Conditions like schizophrenia, depression, and attention-deficit/hyperactivity disorder (ADHD) are known to compromise this cognitive function.
Led by Professors Andreas Papassotiropoulos and Dominique de Quervain, the research team conducted a study involving 43 healthy adults to assess the effects of fampridine on working memory. The results revealed that fampridine notably improved working memory performance in participants with initially low baseline scores. After three days of treatment, these individuals outperformed those who received a placebo. Conversely, the drug had no significant impact on participants who already exhibited strong working memory capabilities.
Additionally, the study found that fampridine increased brain excitability across all participants, potentially facilitating faster processing of information. The research was conducted using a randomized, double-blind methodology to ensure the validity of the results.
While fampridine does not enhance working memory for everyone, it presents a promising treatment avenue for those with cognitive impairments. Professor Papassotiropoulos emphasized, “Fampridine could be a treatment option for those with reduced working memory.”
In light of these findings, the researchers are collaborating with the University Psychiatric Clinics Basel (UPK) to design further studies aimed at evaluating the efficacy of fampridine in treating schizophrenia and depression.
Fampridine is primarily known for its role in improving mobility in MS patients. Its formulation, particularly in slow-release capsules, has also shown benefits in alleviating cognitive fatigue associated with the condition.
Conclusion
The decision to investigate fampridine for this new application was informed by extensive analyses of genomic data, which identified potential pathways for repurposing established drugs. The researchers noted that fampridine interacts with specific ion channels in nerve cells that may also be implicated in mental disorders like schizophrenia.
As research continues, fampridine may offer hope for individuals struggling with working memory deficits linked to various mental health conditions.
Related Topics:
-
Research Emphasizes That Air Pollution Is A Key Environmental Factor At Risk For Autism
-
Singer Amy Grant Emphasizes The Need For Support To Combat Women’S Heart Disease
-
Research Shows That Nature Is Beneficial For Children’S Mental Health
